AR045671A1 - Moleculas de union de nogo a y su uso farmaceutico - Google Patents
Moleculas de union de nogo a y su uso farmaceuticoInfo
- Publication number
- AR045671A1 AR045671A1 ARP040103334A ARP040103334A AR045671A1 AR 045671 A1 AR045671 A1 AR 045671A1 AR P040103334 A ARP040103334 A AR P040103334A AR P040103334 A ARP040103334 A AR P040103334A AR 045671 A1 AR045671 A1 AR 045671A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding molecule
- seq
- human
- nogo
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Polinucleótido que codifica dicha molécula de unión; un vector de expresión que comprende dicho polinucleótido; un sistema de expresión que comprende un polinucleótido capaz de producir una molécula de unión; una célula huésped aislada que comprende un sistema de expresión como se definió anteriormente; el uso de dicha molécula de unión como un farmacéutico, especialmente en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de unión; y un método para el tratamiento de enfermedades asociadas con la reparación de nervios. Reivindicación 1: Una molécula de unión que es capaz de unirse al polipéptido Nogoa humano (SEC ID NO:%) o NiG humano (SEC ID NO:/) o NiG-D20 humano (SEC ID NO:24) o Nogoa_342-357 humano (SEC ID NO:6) con una constante de disociación <1000 nM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321997.9A GB0321997D0 (en) | 2003-09-19 | 2003-09-19 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045671A1 true AR045671A1 (es) | 2005-11-02 |
Family
ID=29266310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103334A AR045671A1 (es) | 2003-09-19 | 2004-09-16 | Moleculas de union de nogo a y su uso farmaceutico |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090181023A1 (es) |
| EP (3) | EP1668033A2 (es) |
| JP (1) | JP2007527232A (es) |
| KR (1) | KR20060119982A (es) |
| CN (1) | CN1878792A (es) |
| AR (1) | AR045671A1 (es) |
| AU (2) | AU2004274164B2 (es) |
| BR (1) | BRPI0414174B8 (es) |
| CA (1) | CA2538725C (es) |
| CO (1) | CO5680457A2 (es) |
| EC (1) | ECSP066431A (es) |
| GB (1) | GB0321997D0 (es) |
| IL (2) | IL174145A (es) |
| IS (1) | IS8404A (es) |
| MA (1) | MA28088A1 (es) |
| MY (2) | MY158078A (es) |
| NO (1) | NO20061678L (es) |
| NZ (1) | NZ545679A (es) |
| PE (1) | PE20050949A1 (es) |
| RU (1) | RU2380377C2 (es) |
| SG (1) | SG146660A1 (es) |
| TN (1) | TNSN06085A1 (es) |
| TW (1) | TWI372060B (es) |
| WO (1) | WO2005028508A2 (es) |
| ZA (1) | ZA200601842B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2330444T3 (es) * | 2003-12-22 | 2009-12-10 | Glaxo Group Limited | Inmunoglobulinas neutralizantes de nogo-a para el tratamiento de enfermedades neurologicas. |
| SG157418A1 (en) * | 2004-12-01 | 2009-12-29 | Univ Singapore | Nogo a protein fragments as neuronal network- interacting peptides |
| PT1899377E (pt) * | 2005-07-05 | 2012-11-20 | Glaxo Group Ltd | Anticorpos humanizados específicos para nogo-a e suas utilizações farmacêuticas |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| ES2425768T3 (es) * | 2007-11-02 | 2013-10-17 | Novartis Ag | Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas |
| WO2012004773A1 (en) | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
| IN2014KN02952A (es) | 2012-07-05 | 2015-05-08 | Glaxo Group Ltd | |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
| CN114470197B (zh) * | 2022-02-16 | 2023-10-03 | 天津长和生物技术有限公司 | 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用 |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ATE132187T1 (de) | 1989-02-13 | 1996-01-15 | Schering Ag | Fledermausspeichel-plasminogenaktivator vpa-alpha 1 |
| ATE483021T1 (de) * | 1998-07-22 | 2010-10-15 | Smithkline Beecham Ltd | Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns |
| EP1248803B1 (en) * | 2000-01-12 | 2010-05-05 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| WO2003048083A2 (en) * | 2001-11-30 | 2003-06-12 | Biogen Idec Ma Inc. | Antibodies against monocyte chemotactic proteins |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| ES2330444T3 (es) * | 2003-12-22 | 2009-12-10 | Glaxo Group Limited | Inmunoglobulinas neutralizantes de nogo-a para el tratamiento de enfermedades neurologicas. |
-
2003
- 2003-09-19 GB GBGB0321997.9A patent/GB0321997D0/en not_active Ceased
-
2004
- 2004-09-16 AR ARP040103334A patent/AR045671A1/es unknown
- 2004-09-17 RU RU2006112849/13A patent/RU2380377C2/ru active
- 2004-09-17 WO PCT/EP2004/010489 patent/WO2005028508A2/en active Application Filing
- 2004-09-17 EP EP04765380A patent/EP1668033A2/en not_active Withdrawn
- 2004-09-17 JP JP2006526602A patent/JP2007527232A/ja active Pending
- 2004-09-17 EP EP10176103A patent/EP2423225A3/en not_active Withdrawn
- 2004-09-17 TW TW093128254A patent/TWI372060B/zh not_active IP Right Cessation
- 2004-09-17 PE PE2004000908A patent/PE20050949A1/es not_active Application Discontinuation
- 2004-09-17 CN CNA2004800332675A patent/CN1878792A/zh active Pending
- 2004-09-17 AU AU2004274164A patent/AU2004274164B2/en not_active Ceased
- 2004-09-17 US US10/572,434 patent/US20090181023A1/en not_active Abandoned
- 2004-09-17 BR BRPI0414174A patent/BRPI0414174B8/pt not_active IP Right Cessation
- 2004-09-17 KR KR1020067005424A patent/KR20060119982A/ko not_active Application Discontinuation
- 2004-09-17 EP EP10160905A patent/EP2248827A1/en not_active Withdrawn
- 2004-09-17 MY MYPI20043786A patent/MY158078A/en unknown
- 2004-09-17 NZ NZ545679A patent/NZ545679A/en not_active IP Right Cessation
- 2004-09-17 CA CA2538725A patent/CA2538725C/en not_active Expired - Fee Related
- 2004-09-17 MY MYPI2013003188A patent/MY161068A/en unknown
- 2004-09-17 SG SG200806933-8A patent/SG146660A1/en unknown
-
2006
- 2006-03-03 ZA ZA200601842A patent/ZA200601842B/en unknown
- 2006-03-06 IL IL174145A patent/IL174145A/en active IP Right Grant
- 2006-03-17 TN TNP2006000085A patent/TNSN06085A1/en unknown
- 2006-03-17 EC EC2006006431A patent/ECSP066431A/es unknown
- 2006-03-29 CO CO06031001A patent/CO5680457A2/es active IP Right Grant
- 2006-04-07 MA MA28921A patent/MA28088A1/fr unknown
- 2006-04-10 IS IS8404A patent/IS8404A/is unknown
- 2006-04-12 NO NO20061678A patent/NO20061678L/no not_active Application Discontinuation
-
2009
- 2009-01-22 AU AU2009200237A patent/AU2009200237B2/en not_active Ceased
- 2009-12-28 IL IL203007A patent/IL203007A/en active IP Right Grant
-
2010
- 2010-06-16 US US12/816,964 patent/US20110008334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066431A (es) | Moléculas de unión de nogo-a y uso farmacéutico de las mismas | |
| Bab et al. | Osteogenic growth peptide: from concept to drug design | |
| TN2009000190A1 (en) | Lingo binding molecules and pharmaceutical use thereof | |
| CO6362020A2 (es) | Mutantes fgf21 y uso de los mismos | |
| CO6470863A2 (es) | Mutantes fgf21 y usos de los mismos | |
| BR0315666A (pt) | Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos | |
| DE60224291D1 (de) | System zur antikörperexpression und- synthese | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| CL2008001634A1 (es) | Anticuerpo de la region regulatoria negativa anti-notch1 aislado; polinucleotido que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; y su uso para preparar un medicamento para tratar un trastorno asociado con un aumento en la señalizacion o expresion de notch1 en un individuo. | |
| EA201270758A1 (ru) | Мутанты fgf21 и их применение | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| Cychon et al. | Stylissamides E and F, cyclic heptapeptides from the Caribbean sponge Stylissa caribica | |
| AR072934A1 (es) | Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas | |
| AR069958A1 (es) | Metodo para producir una proteina heterologa de interes | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| Brennan et al. | Stylopeptide 2, a proline-rich cyclodecapeptide from the sponge Stylotella sp. | |
| Wang et al. | Discovery of two P-superfamily conotoxins, lt9a and lt9b, with different modifications on voltage-sensitive sodium channels | |
| AR114444A1 (es) | Método de secuenciación para terapia de células t con car | |
| TH71697A (th) | โมเลกุลสำหรับจับ nogo-a และการใช้สารเหล่านี้ในทางยา |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |